Led · Seed · Jul 2026

Immitra Bio is developing scalable, one-time curative in-vivo gene editing therapies built around a mutation-agnostic editing approach and a digital target discovery platform. Its lead candidate, IB-003, is being developed as a potential one-time curative in-vivo gene editing treatment for an inherited anemia. The company's approach is designed to avoid complex ex-vivo cell manipulation, patient conditioning, and stem cell transplantation, aiming to enable off-the-shelf formulations that treat all patients within a given disease regardless of underlying mutation. Immitra Bio says its platform could generate dozens of differentiated therapeutic assets more quickly than highly personalized approaches. The recent CHF 2.4 million pre-seed financing will primarily fund preclinical proof-of-concept work for IB-003 and support additional discovery and validation across the pipeline and platform refinement. The company highlights scalability and commercial viability as core objectives for its technology.

Participated · Series C · Oct 2025

Tubulis is a Munich-based biotechnology company engineering uniquely matched antibody-drug conjugates with enhanced biophysical properties for improved on-tumor delivery and wider therapeutic windows. Its proprietary Tubutecan and other ADC platform technologies underpin a growing pipeline designed for high-need solid tumor indications. The lead program, TUB-040 targeting NaPi2b, has shown early clinical proof-of-concept in platinum-resistant high-grade serous ovarian cancer, demonstrating anti-tumor activity at low doses with favorable safety. A second clinical-stage candidate, TUB-030, targets 5T4, and several additional ADCs remain in preclinical development. Proceeds from the company’s latest financing will fund pivotal trials of TUB-040, evaluations in earlier-line ovarian cancer, combination regimens and broader solid tumor exploration. The capital will also advance TUB-030 and preclinical assets while driving further innovation of Tubulis’ ADC technologies for internal programs and partnerships. To date, the firm has secured €344 million (US $401 million) in Series C funding from a global syndicate of life-science investors.

Participated · Series B · Mar 2024

Hemotune is a developer of blood‑purification technology based on nano magnetic beads. The company has built a bead‑based blood‑purification platform intended for treatment of human diseases. Hemotune recently completed a CHF14 million Series B financing. The round was led by Belmondo, with existing investors VP Venture Partners, HEMEX, OCCIDENT and Zürcher Kantonalbank continuing to participate and EFI joining the round. Proceeds from the financing will be used to advance development of the company’s HemoSystem, described as a breakthrough blood‑purification platform based on nano‑engineered magnetic beads. No operating metrics, founding year, or location were provided in the article. Hemotune’s core product, HemoSystem, is a blood purification platform that mixes nanoengineered magnetic beads directly with patients’ blood in a dialysis-like machine and removes beads and bound targets via a magnetic filter before recirculation. The company says the system offers much higher efficiency and precision compared with existing methods. Its first therapy under development is designed to restore adequate immune response in sepsis-associated immunosuppression. Hemotune intends to use the recent funding to complete preclinical development of HemoSystem and to prepare a clinical trial in sepsis, its lead indication. The company highlights sepsis as an underserved global health issue that leads to around 11 million deaths annually. Hemotune was founded in 2017 as a spin-off from ETH Zurich and is being accelerated by Wyss Zurich. The company closed a CHF 7.25 million Series B1 to support these development and clinical-preparation efforts. Hemotune AG is a spin‑off from ETH Zurich (founded 2017) developing HemoSystem, a blood purification platform that mixes nanoengineered magnetic beads directly with patient blood in a dialysis‑like machine. The beads are roughly 300 times smaller than a red blood cell and are coated with selective binding agents to capture disease‑related compounds. While blood flows through a magnetic filter, beads and bound targets are removed before recirculation, with the aim of removing substances that play key roles in immune response and sepsis. With the Series A close hemotune will accelerate preclinical development of HemoSystem and pursue first launches in Europe. The company is incubated at Wyss Zurich and is positioning the technology for septic shock and other indications, with potential relevance to COVID‑19. Hemotune has built industry partnerships to support geographic expansion, notably with Korean partner GCMS for Asian market entry. The company has raised more than CHF 10 million in total since incorporation.

Led · Series A · Feb 2024

Founded in 2021, Altavo is a Dresden-based medical device startup focused on AI-powered voice rehabilitation. Its core technology combines non-invasive radar sensing with artificial intelligence to create prosthetic solutions that help aphonic and severely voice-impaired patients regain natural speech. The company collaborates with the Chair of Speech Technology and Cognitive Systems and the Chair of Radio Frequency Engineering at Dresden University of Technology. Altavo employs 16 specialists across AI/data science, speech technology, radio-frequency engineering, medical devices and speech therapy at its Dresden and Jena offices. The newly secured capital will accelerate company development, fund clinical work, and advance its commercial product toward market readiness. While still pre-revenue, the startup’s growing R&D partnerships and specialized team position it to address a significant unmet clinical need.

Led · Seed · Jan 2024

Chipmetrics develops metrology solutions for semiconductor manufacturing focused on atomic layer deposition (ALD) process conformality. Its core product is the PillarHall® metrology chip, and the company sells metrology chips and measurement services to characterize thin-film processes. Led by founder and CEO Mikko Utriainen, Chipmetrics was founded in 2019 and is headquartered in Joensuu, Finland. The company has employees and sales partners in Japan, South Korea, the USA and Germany. Chipmetrics raised a €2.4M Seed round and said it will use the proceeds to enhance its product portfolio, refine its measurement solutions, and reinforce its global sales network.